[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvuD_Ug5CxNMpaRJbOIGej1RUbqr4UX7Ao4nr2Lnnrzo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":54,"rows":61},"Hospital do Coracao",[4],67,false,16,14,104764,8,49,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Covid19",4,{"name":18,"count":19},"Obesity",3,{"name":21,"count":19},"Cardiovascular Diseases",{"name":23,"count":19},"Familial Hypercholesterolemia",{"name":25,"count":19},"Heart Failure",{"name":27,"count":19},"Coronary Artery Disease",{"name":29,"count":19},"Acute Respiratory Distress Syndrome",{"name":31,"count":32},"Breast Cancer",2,[34,39,44,49],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06547892","Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU","2025-10-10","Vasopressin",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05764044","Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer","2026-12-31","cisplatin, gemcitabine",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06464510","Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis","2027-08","Early Vasopressin",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06930885","Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","2031-05","Cardiovascular Polypill",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,88,111,129,154,172,190,208,230,269,296,314,332,359,377,405,423,441,467,495,513,538,564,582,606,631,649,675,693,719,737],{"intervention":43,"totalTrials":63,"cells":64},1,{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":72,"PHASE4":84,"NA":86},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":67},[],{"trials":73,"activeCount":63,"soonestReadout":42},[74],{"nctId":40,"briefTitle":41,"status":75,"phases":76,"primaryCompletion":42,"completion":42,"start":77,"enrollment":78,"conditions":79,"interventions":83},"RECRUITING",[58],"2024-03-27",365,[80,81,82],"Cervical Cancer","Cervix Cancer","Cervix Neoplasm",[43],{"trials":85,"activeCount":67},[],{"trials":87,"activeCount":67},[],{"intervention":48,"totalTrials":63,"cells":89},{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":107,"NA":109},{"trials":91,"activeCount":67},[],{"trials":93,"activeCount":67},[],{"trials":95,"activeCount":67},[],{"trials":97,"activeCount":63,"soonestReadout":47},[98],{"nctId":45,"briefTitle":46,"status":75,"phases":99,"primaryCompletion":47,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":105},[58],"2027-09","2024-11-21",2800,[104],"Septic Shock",[48,106],"Norepinephrine and Vasopressin for Rescue",{"trials":108,"activeCount":67},[],{"trials":110,"activeCount":67},[],{"intervention":106,"totalTrials":63,"cells":112},{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":125,"NA":127},{"trials":114,"activeCount":67},[],{"trials":116,"activeCount":67},[],{"trials":118,"activeCount":67},[],{"trials":120,"activeCount":63,"soonestReadout":47},[121],{"nctId":45,"briefTitle":46,"status":75,"phases":122,"primaryCompletion":47,"completion":100,"start":101,"enrollment":102,"conditions":123,"interventions":124},[58],[104],[48,106],{"trials":126,"activeCount":67},[],{"trials":128,"activeCount":67},[],{"intervention":53,"totalTrials":63,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":150,"NA":152},{"trials":132,"activeCount":67},[],{"trials":134,"activeCount":67},[],{"trials":136,"activeCount":67},[],{"trials":138,"activeCount":63,"soonestReadout":52},[139],{"nctId":50,"briefTitle":51,"status":75,"phases":140,"primaryCompletion":52,"completion":52,"start":141,"enrollment":142,"conditions":143,"interventions":146},[58],"2025-06-12",7713,[144,145],"Atherothrombotic Diseases","Atherosclerotic Cardiovascular Disease (ASCVD)",[53,147,148,149],"Colchicine 0.5 mg","Usual Care Group","Colchicine-placebo 0.5 mg",{"trials":151,"activeCount":67},[],{"trials":153,"activeCount":67},[],{"intervention":147,"totalTrials":63,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":168,"NA":170},{"trials":157,"activeCount":67},[],{"trials":159,"activeCount":67},[],{"trials":161,"activeCount":67},[],{"trials":163,"activeCount":63,"soonestReadout":52},[164],{"nctId":50,"briefTitle":51,"status":75,"phases":165,"primaryCompletion":52,"completion":52,"start":141,"enrollment":142,"conditions":166,"interventions":167},[58],[144,145],[53,147,148,149],{"trials":169,"activeCount":67},[],{"trials":171,"activeCount":67},[],{"intervention":148,"totalTrials":63,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":186,"NA":188},{"trials":175,"activeCount":67},[],{"trials":177,"activeCount":67},[],{"trials":179,"activeCount":67},[],{"trials":181,"activeCount":63,"soonestReadout":52},[182],{"nctId":50,"briefTitle":51,"status":75,"phases":183,"primaryCompletion":52,"completion":52,"start":141,"enrollment":142,"conditions":184,"interventions":185},[58],[144,145],[53,147,148,149],{"trials":187,"activeCount":67},[],{"trials":189,"activeCount":67},[],{"intervention":149,"totalTrials":63,"cells":191},{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":204,"NA":206},{"trials":193,"activeCount":67},[],{"trials":195,"activeCount":67},[],{"trials":197,"activeCount":67},[],{"trials":199,"activeCount":63,"soonestReadout":52},[200],{"nctId":50,"briefTitle":51,"status":75,"phases":201,"primaryCompletion":52,"completion":52,"start":141,"enrollment":142,"conditions":202,"interventions":203},[58],[144,145],[53,147,148,149],{"trials":205,"activeCount":67},[],{"trials":207,"activeCount":67},[],{"intervention":38,"totalTrials":63,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":211,"activeCount":67},[],{"trials":213,"activeCount":67},[],{"trials":215,"activeCount":63,"soonestReadout":37},[216],{"nctId":35,"briefTitle":36,"status":75,"phases":217,"primaryCompletion":37,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},[57],"2025-12-10","2025-04-10",60,[222],"Critical Illness",[38],{"trials":225,"activeCount":67},[],{"trials":227,"activeCount":67},[],{"trials":229,"activeCount":67},[],{"intervention":231,"totalTrials":32,"cells":232},"Atorvastatin",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":254,"NA":267},{"trials":234,"activeCount":67},[],{"trials":236,"activeCount":67},[],{"trials":238,"activeCount":67},[],{"trials":240,"activeCount":67},[241],{"nctId":242,"briefTitle":243,"status":244,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":253},"NCT01543555","Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose","COMPLETED",[58],"2015-06","2012-11",648,[250,251,252],"Myocardial Infarction","Peripheral Vascular Disease","Aortic Aneurism",[231],{"trials":255,"activeCount":67},[256],{"nctId":257,"briefTitle":258,"status":244,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":266},"NCT01448642","Statins Evaluation in Coronary Procedures and Revascularization Trial",[59],"2017-11","2018-04","2012-04",4191,[265],"Acute Coronary Syndrome",[231],{"trials":268,"activeCount":67},[],{"intervention":270,"totalTrials":63,"cells":271},"Atazanavir",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":292,"NA":294},{"trials":273,"activeCount":67},[],{"trials":275,"activeCount":67},[],{"trials":277,"activeCount":67},[],{"trials":279,"activeCount":67},[280],{"nctId":281,"briefTitle":282,"status":244,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":289},"NCT04468087","Antiviral Agents Against COVID-19 Infection",[57,58],"2021-08-04","2021-02-15",256,[288],"COVID-19",[270,290,291],"Daclatasvir 60 mg","Sofusbuvir + Daclastavir 60 mg",{"trials":293,"activeCount":67},[],{"trials":295,"activeCount":67},[],{"intervention":290,"totalTrials":63,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":310,"NA":312},{"trials":299,"activeCount":67},[],{"trials":301,"activeCount":67},[],{"trials":303,"activeCount":67},[],{"trials":305,"activeCount":67},[306],{"nctId":281,"briefTitle":282,"status":244,"phases":307,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":308,"interventions":309},[57,58],[288],[270,290,291],{"trials":311,"activeCount":67},[],{"trials":313,"activeCount":67},[],{"intervention":291,"totalTrials":63,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":328,"NA":330},{"trials":317,"activeCount":67},[],{"trials":319,"activeCount":67},[],{"trials":321,"activeCount":67},[],{"trials":323,"activeCount":67},[324],{"nctId":281,"briefTitle":282,"status":244,"phases":325,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":326,"interventions":327},[57,58],[288],[270,290,291],{"trials":329,"activeCount":67},[],{"trials":331,"activeCount":67},[],{"intervention":333,"totalTrials":63,"cells":334},"Plasma-Lyte",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":355,"NA":357},{"trials":336,"activeCount":67},[],{"trials":338,"activeCount":67},[],{"trials":340,"activeCount":67},[],{"trials":342,"activeCount":67},[343],{"nctId":344,"briefTitle":345,"status":244,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":353},"NCT02875873","Balanced Solution Versus Saline in Intensive Care Study",[58],"2020-03-02","2021-02-28","2017-05-27",11075,[222,352],"Acute Kidney Injury",[333,354],"Saline 0.9%",{"trials":356,"activeCount":67},[],{"trials":358,"activeCount":67},[],{"intervention":354,"totalTrials":63,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":373,"NA":375},{"trials":362,"activeCount":67},[],{"trials":364,"activeCount":67},[],{"trials":366,"activeCount":67},[],{"trials":368,"activeCount":67},[369],{"nctId":344,"briefTitle":345,"status":244,"phases":370,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":371,"interventions":372},[58],[222,352],[333,354],{"trials":374,"activeCount":67},[],{"trials":376,"activeCount":67},[],{"intervention":378,"totalTrials":63,"cells":379},"polipillV1",{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":386,"PHASE4":401,"NA":403},{"trials":381,"activeCount":67},[],{"trials":383,"activeCount":67},[],{"trials":385,"activeCount":67},[],{"trials":387,"activeCount":67},[388],{"nctId":389,"briefTitle":390,"status":391,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":67,"conditions":396,"interventions":398},"NCT01313702","Single Pill to Avert Cardiovascular Events","WITHDRAWN",[58],"2014-04","2014-07","2012-10",[397],"Cardiovascular Disease",[378,399,400],"polipillV2","usual care",{"trials":402,"activeCount":67},[],{"trials":404,"activeCount":67},[],{"intervention":399,"totalTrials":63,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":419,"NA":421},{"trials":408,"activeCount":67},[],{"trials":410,"activeCount":67},[],{"trials":412,"activeCount":67},[],{"trials":414,"activeCount":67},[415],{"nctId":389,"briefTitle":390,"status":391,"phases":416,"primaryCompletion":393,"completion":394,"start":395,"enrollment":67,"conditions":417,"interventions":418},[58],[397],[378,399,400],{"trials":420,"activeCount":67},[],{"trials":422,"activeCount":67},[],{"intervention":400,"totalTrials":63,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":437,"NA":439},{"trials":426,"activeCount":67},[],{"trials":428,"activeCount":67},[],{"trials":430,"activeCount":67},[],{"trials":432,"activeCount":67},[433],{"nctId":389,"briefTitle":390,"status":391,"phases":434,"primaryCompletion":393,"completion":394,"start":395,"enrollment":67,"conditions":435,"interventions":436},[58],[397],[378,399,400],{"trials":438,"activeCount":67},[],{"trials":440,"activeCount":67},[],{"intervention":442,"totalTrials":63,"cells":443},"Stromal Cells",{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":463,"NA":465},{"trials":445,"activeCount":67},[],{"trials":447,"activeCount":67},[],{"trials":449,"activeCount":67},[],{"trials":451,"activeCount":67},[452],{"nctId":453,"briefTitle":454,"status":391,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":67,"conditions":459,"interventions":462},"NCT04005989","Adipose Stromal Cells Injection in the Myocardium for Induction of Revascularization",[58],"2022-11-30","2022-12-20","2021-12-01",[460,461,27],"Ischemic Heart Disease","Myocardial Ischemia",[442],{"trials":464,"activeCount":67},[],{"trials":466,"activeCount":67},[],{"intervention":468,"totalTrials":63,"cells":469},"Ticagrelor 180 mg",{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":491,"NA":493},{"trials":471,"activeCount":67},[],{"trials":473,"activeCount":67},[],{"trials":475,"activeCount":67},[],{"trials":477,"activeCount":67},[478],{"nctId":479,"briefTitle":480,"status":244,"phases":481,"primaryCompletion":482,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":489},"NCT02298088","Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis",[58],"2017-12","2019-01","2015-08",3799,[487,488],"Acute ST Segment Elevation Myocardial Infarction","Thrombolysis in Myocardial Infarction Flow",[468,490],"Clopidogrel",{"trials":492,"activeCount":67},[],{"trials":494,"activeCount":67},[],{"intervention":490,"totalTrials":63,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":509,"NA":511},{"trials":498,"activeCount":67},[],{"trials":500,"activeCount":67},[],{"trials":502,"activeCount":67},[],{"trials":504,"activeCount":67},[505],{"nctId":479,"briefTitle":480,"status":244,"phases":506,"primaryCompletion":482,"completion":483,"start":484,"enrollment":485,"conditions":507,"interventions":508},[58],[487,488],[468,490],{"trials":510,"activeCount":67},[],{"trials":512,"activeCount":67},[],{"intervention":514,"totalTrials":63,"cells":515},"Acetylcysteine",{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":534,"NA":536},{"trials":517,"activeCount":67},[],{"trials":519,"activeCount":67},[],{"trials":521,"activeCount":67},[],{"trials":523,"activeCount":67},[524],{"nctId":525,"briefTitle":526,"status":244,"phases":527,"primaryCompletion":528,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":533},"NCT00736866","The Acetylcysteine for Contrast-Induced Nephropathy Trial",[58],"2010-07","2008-08",2300,[532],"Acute Kidney Failure",[514],{"trials":535,"activeCount":67},[],{"trials":537,"activeCount":67},[],{"intervention":539,"totalTrials":63,"cells":540},"Hydroxychloroquine Oral Product",{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":560,"NA":562},{"trials":542,"activeCount":67},[],{"trials":544,"activeCount":67},[],{"trials":546,"activeCount":67},[],{"trials":548,"activeCount":67},[549],{"nctId":550,"briefTitle":551,"status":244,"phases":552,"primaryCompletion":553,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":558},"NCT04322123","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)",[58],"2020-06-02","2020-04-01",667,[557],"Coronavirus Infections",[539,559],"Hydroxychloroquine + azithromycin",{"trials":561,"activeCount":67},[],{"trials":563,"activeCount":67},[],{"intervention":559,"totalTrials":63,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":578,"NA":580},{"trials":567,"activeCount":67},[],{"trials":569,"activeCount":67},[],{"trials":571,"activeCount":67},[],{"trials":573,"activeCount":67},[574],{"nctId":550,"briefTitle":551,"status":244,"phases":575,"primaryCompletion":553,"completion":553,"start":554,"enrollment":555,"conditions":576,"interventions":577},[58],[557],[539,559],{"trials":579,"activeCount":67},[],{"trials":581,"activeCount":67},[],{"intervention":583,"totalTrials":63,"cells":584},"A vaccine composed of a recombinant S1 antigen",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":586,"activeCount":67},[],{"trials":588,"activeCount":67},[],{"trials":590,"activeCount":67},[591],{"nctId":592,"briefTitle":593,"status":391,"phases":594,"primaryCompletion":595,"completion":596,"start":597,"enrollment":67,"conditions":598,"interventions":599},"NCT05016934","Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized",[56,57],"2022-03-04","2022-04-20","2021-11-01",[15],[583],{"trials":601,"activeCount":67},[],{"trials":603,"activeCount":67},[],{"trials":605,"activeCount":67},[],{"intervention":607,"totalTrials":63,"cells":608},"Rivaroxaban",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":610,"activeCount":67},[],{"trials":612,"activeCount":67},[],{"trials":614,"activeCount":67},[615],{"nctId":616,"briefTitle":617,"status":244,"phases":618,"primaryCompletion":619,"completion":619,"start":484,"enrollment":620,"conditions":621,"interventions":623},"NCT02303795","RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial",[57],"2020-08",1005,[622],"Valvular Heart Disease",[607,624],"Warfarin",{"trials":626,"activeCount":67},[],{"trials":628,"activeCount":67},[],{"trials":630,"activeCount":67},[],{"intervention":624,"totalTrials":63,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":643,"PHASE4":645,"NA":647},{"trials":634,"activeCount":67},[],{"trials":636,"activeCount":67},[],{"trials":638,"activeCount":67},[639],{"nctId":616,"briefTitle":617,"status":244,"phases":640,"primaryCompletion":619,"completion":619,"start":484,"enrollment":620,"conditions":641,"interventions":642},[57],[622],[607,624],{"trials":644,"activeCount":67},[],{"trials":646,"activeCount":67},[],{"trials":648,"activeCount":67},[],{"intervention":650,"totalTrials":63,"cells":651},"PJS-539 Dose 1",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":653,"activeCount":67},[],{"trials":655,"activeCount":67},[],{"trials":657,"activeCount":67},[658],{"nctId":659,"briefTitle":660,"status":244,"phases":661,"primaryCompletion":662,"completion":595,"start":663,"enrollment":664,"conditions":665,"interventions":667},"NCT05008393","Efficacy of PJS-539 for Adult Patients With COVID-19.",[57],"2022-02-03","2021-09-25",153,[15,666],"COVID-19 Pneumonia",[650,668],"PJS-539 Dose 2",{"trials":670,"activeCount":67},[],{"trials":672,"activeCount":67},[],{"trials":674,"activeCount":67},[],{"intervention":668,"totalTrials":63,"cells":676},{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":687,"PHASE4":689,"NA":691},{"trials":678,"activeCount":67},[],{"trials":680,"activeCount":67},[],{"trials":682,"activeCount":67},[683],{"nctId":659,"briefTitle":660,"status":244,"phases":684,"primaryCompletion":662,"completion":595,"start":663,"enrollment":664,"conditions":685,"interventions":686},[57],[15,666],[650,668],{"trials":688,"activeCount":67},[],{"trials":690,"activeCount":67},[],{"trials":692,"activeCount":67},[],{"intervention":694,"totalTrials":63,"cells":695},"ISIS 721744",{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":697,"activeCount":67},[],{"trials":699,"activeCount":67},[],{"trials":701,"activeCount":67},[702],{"nctId":703,"briefTitle":704,"status":244,"phases":705,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":711},"NCT04549922","Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19",[57],"2020-12-09","2021-12-09","2020-10-19",111,[15],[694,712],"Normal Saline",{"trials":714,"activeCount":67},[],{"trials":716,"activeCount":67},[],{"trials":718,"activeCount":67},[],{"intervention":712,"totalTrials":63,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":731,"PHASE4":733,"NA":735},{"trials":722,"activeCount":67},[],{"trials":724,"activeCount":67},[],{"trials":726,"activeCount":67},[727],{"nctId":703,"briefTitle":704,"status":244,"phases":728,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":729,"interventions":730},[57],[15],[694,712],{"trials":732,"activeCount":67},[],{"trials":734,"activeCount":67},[],{"trials":736,"activeCount":67},[],{"intervention":738,"totalTrials":63,"cells":739},"Nicotine replacement",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":741,"activeCount":67},[],{"trials":743,"activeCount":67},[],{"trials":745,"activeCount":67},[],{"trials":747,"activeCount":67},[],{"trials":749,"activeCount":67},[],{"trials":751,"activeCount":67},[752],{"nctId":753,"briefTitle":754,"status":244,"phases":755,"primaryCompletion":756,"completion":247,"start":528,"enrollment":757,"conditions":758,"interventions":760},"NCT01734330","Cognitive Behaviour Therapy and Nicotine Replacement to Increase Tobacco Cessation",[60],"2012-09",200,[759],"Smokers",[738]]